Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

NCT06371586 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Diffuse Type Carcinoma

Interventions

DRUG: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences